Artificial Intelligence is Changing the Face of Pharmacovigilance
페이지 정보
본문
Artificial Intelligence is Transforming the Landscape of Pharmacovigilance
In 2021, over 2.2 million Adverse Event (AE) reports were submitted to the FAERS database, prompting the FDA to unveil a five-year strategic plan to integrate AI into existing PV frameworks. As the volume of reported AEs continues to surge, PV and drug safety specialists are facing an increasing burden to assess data with both precision and speed. Consequently, implementing advanced technologies has become paramount to alleviating specialist workloads while ensuring the accurate and systematic evaluation of large-scale datasets.
AI-driven pharmacovigilance leverages diverse methodologies and models, including Machine Learning (ML) and Deep Learning (DL). Integrating AI into PV workflows not only streamlines operational efficiency for safety specialists but also empowers them to focus on high-value, strategic tasks.
